- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00207311
Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus (HCVNASH)
A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent evidence suggests that patients with concomitant chronic HCV infection and NASH or significant hepatic steatosis (>33%) respond less well to standard antiviral therapy. As previously noted, up to 10% of patients with chronic HCV infection will have concomitant NASH and an even greater percentage will have associated hepatic steatosis. No prospective studies to date have evaluated the sustained viral response rates to standard antiviral therapy in this group of patients who were previously treated with a medication to eliminate or improve the underlying NASH and/or hepatic steatosis.
Primary Outcome: To determine if decreasing the amount of NASH or hepatic steatosis in overweight (BMI >27 kg/m2) HCV patients results in improved overall SVR to PEGASYS and Copegus.
Secondary Outcome: 1.To determine the amount of steatosis, necroinflammatory activity, and fibrosis change in a group of participants with chronic hepatitis C and NASH or significant steatosis treated with Xenical vs. placebo for 36 weeks. 2. To assess for a difference in insulin resistance, as measured by the QUICKI score, before and after treatment with Xenical or Xenical placebo and diet and exercise.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Texas
-
Ft. Sam Houston, Texas, United States, 78234
- Brooke Army Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be willing to give written informed consent and be able to adhere to dose and visit schedules.
- HCV-Ab or HCV-RNA by PCR Positive for at least 6 months
- Serum positive for HCV-RNA by PCR assay
- Treatment naïve participants who have hepatitis C with genotype 1, 2, 3, or 4
- Body mass index >27
- Liver biopsy within 12 months with a pathology report confirming the histological diagnosis consistent with CHCand NASH or hepatic steatosis of >33%
Compensated liver disease with minimum hematological, biochemical, and serologic criteria at the Enrollment Visit (WNL = within normal limits):
- Hemoglobin values of <12 gm/dL for females and <13 gm/dL for males
- WBC <3,000/ mm3
- Neutrophil count < 1,500/mm3
- Platelets <65,000/ mm3
- Direct bilirubin within 20% of ULN
- Indirect bilirubin WNL
- Albumin > 3 gm/dL
- creatinine < 20% of ULN
- TSH WNL
- Alpha fetoprotein value < 100 ng/mL
- Reconfirmation and documentation that sexually active female subjects of childbearing potential are practicing adequate contraception method, or monogamous relationship with a male partner who has had a vasectomy or is using a condom + spermicide) during the treatment period and for six months following the last dose of study medication
- Reconfirmation that sexually active male subjects are practicing two acceptable methods of contraception
Exclusion Criteria:
- Women who are pregnant or breast-feeding
- Males whose female partner is pregnant
- No other Thiazolidinedione after liver biopsy and/or during the entire study
- Hepatitis C of non-genotype 1,2,3 or 4
- Previous anti-viral therapy for treatment of Hepatitis C
- Suspected hypersensitivity to interferon, PEG-interferon, ribavirin, Xenical
Any other cause for liver disease other than chronic hepatitis C and NASH or steatosis, including but not limited to:
- Hemochromatosis
- Alpha-1 antitrypsin deficiency
- Co-infection with HBV
- Wilson's disease
- Autoimmune hepatitis
- Alcoholic liver disease
- Drug-related liver disease
- Any condition that would prevent the subject from having a liver biopsy
- Hemoglobinopathies (e.g., Beta Thalassemia)
- Evidence of advanced liver disease
- Patients with organ transplants other than cornea and hair transplant
Any known preexisting medical condition that could interfere with the subject's participation in and completion of the protocol such as:
- Preexisting psychiatric condition, especially severe depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt are excluded
- CNS trauma or preexisting/active seizure disorders uncontrolled with medication
- Significant cardiovascular dysfunction within the past 12 months
- Poorly controlled diabetes mellitus
- Chronic pulmonary disease with documented pulmonary hypertension
- Immunologically mediated disease (Crohn's disease, ulcerative colitis), rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, clinical cryoglobulinemia with vasculitis
- Any medical condition requiring, or likely to require chronic systemic administration of steroids
- Evidence of an active or suspected cancer or a history of malignancy where the risk of reoccurrence is ≥ 20% within 2 years
- Active clinical gout
- Substance abuse
- Participants not willing to be counseled/abstain from alcohol
- Participants with clinically severe retinal abnormalities
- Any other condition that in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the protocol
- Known positive HIV
- Inability/unwillingness to provide informed consent or abide by the requirements of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Xenical placebo
Xenical placebo PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
|
Xenicare program for 36 weeks.
Other Names:
|
ACTIVE_COMPARATOR: Xenical (orlistat)
Xenical (orlistat) 120mg PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
|
Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1).
Pegasys 180 mcg weekly for 48 weeks.
Ribavirin daily for 48 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sustained virological response (SVR) defined as the percentage of participants with undetectable HCV-RNA as measured by the Roche AMPLICORTM HCV Test, v 2.0 (detection limit 50 IU/mL) at 24 weeks post completion of the treatment period
Time Frame: 110 weeks
|
110 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hepatic steatosis, necroinflammatory activity and fibrosis improvement at week 36 as determined by Dr. Elizabeth Brunt at Saint Louis University
Time Frame: 36 weeks
|
36 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Fatty Liver
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Lipid Regulating Agents
- Anti-Obesity Agents
- Interferons
- Interferon-alpha
- Peginterferon alfa-2a
- Interferon alpha-2
- Orlistat
Other Study ID Numbers
- C.2004.140
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Sohag UniversityRecruiting
Clinical Trials on Xenicare Program
-
University of California, Los AngelesUniversity of California, San Francisco; Stanford University; California Initiative...Enrolling by invitationStress | Stress, Psychological | Stress, Emotional | Stress, Physiological | Stress ReactionUnited States
-
National Taiwan University HospitalCompleted
-
University of Maryland, BaltimoreNational Institute of Nursing Research (NINR)CompletedOsteoporosis | Health Behaviors
-
University of AlcalaRecruitingLateral EpicondylitisSpain
-
Massachusetts General HospitalRecruitingPancreatic Ductal AdenocarcinomaUnited States
-
University of CagliariSuspended
-
University of Kansas Medical CenterUnknownUpper Extremity Injuries | Elbow Injuries | Sprain Ulnar Collateral Ligament | Strain of Ulnar Collateral Ligament | Complete Tear Ulnar Collateral LigamentUnited States
-
Sunnybrook Health Sciences CentreToronto Rehabilitation InstituteCompleted
-
Massachusetts General HospitalCompleted
-
Azienda Sanitaria Locale CN1 CuneoNot yet recruiting